Bristol-Myers Squibb Co (NYSE:BMY)

65.63
Delayed Data
As of Feb 21
 +0.46 / +0.71%
Today’s Change
42.48
Today|||52-Week Range
68.34
+2.24%
Year-to-Date
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
9:32am / MotleyFool.com - Paid Partner Content
Better Buy: Biogen vs. Bristol-Myers Squibb
Feb 16 / MotleyFool.com - Paid Partner Content
3 Cancer Treatment Stocks to Buy Right Now
7:31am / MotleyFool.com - Paid Partner Content
3 High-Yielding U.S. Pharmaceutical Companies to Consider
Feb 15 / MotleyFool.com - Paid Partner Content
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Feb 22 / MotleyFool.com - Paid Partner Content
Could This Cancer Drug Developer’s Stock Make You Rich?
Feb 14 / MotleyFool.com - Paid Partner Content
FDA Approved 1,014 Generic Drugs in 2019
Feb 19 / MotleyFool.com - Paid Partner Content
White House Claims Other Countries Are "Free-Riding" on U.S. Drug Development
Feb 13 / MotleyFool.com - Paid Partner Content
Why bluebird bio's Q4 Results Really Don't Matter
Feb 19 / MotleyFool.com - Paid Partner Content
FDA Gives Bristol-Myers Squibb's CAR-T Liso-Cel a Priority Review
Feb 13 / MotleyFool.com - Paid Partner Content
Better Buy: GlaxoSmithKline vs. Bristol-Myers Squibb
Feb 16 / MotleyFool.com - Paid Partner Content
Bristol-Myers Squibb Stock Is Too Cheap to Ignore
Feb 10 / MotleyFool.com - Paid Partner Content